Tender Details
Ref No 24244188
Document

Tender Notice

Bidding

Not specified

Short Description

A. Laronidase (Genetically Recombinant) (2.9Mg 5Ml X 1 Bottle/Box) 2,025 Boxes, B. Labulizumab (Genetically Recombinant) (300Mg 3Ml X 1 Bottle/Box) 242 Boxes, C. Labulizumab (Genetically Recombinant) (1100Mg 11Ml X 1 Bottle/Box) 68 Boxes...
Deadline *
Date 07 Feb 2026
* The estimated cost, values & dates are indicative only. Please read tender document for accurate information.
Client Address
Location Japan
More Information
Know More

FREE Trial Plan For All New Users!

Start your Business.

Similar Tenders

  • Ref No: 8259327
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements According To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Cre 2 5 Mg N1

  • Deadline: 10 May 2026
  • Ref No: 8260726
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Hydrocortisone Tab 10 Mg

  • Deadline: 10 May 2026
  • Ref No: 5310892
  • Location: Germany

Drug Contracts With An Option To Join

  • Deadline: 01 May 2026
  • Ref No: 5301821
  • Location: Bulgaria

Delivery Of Medicinal Products Which Are Included In Appendix 2 Of The Pds For The Needs Of Umbal Kanev Ad

  • Deadline: 27 May 2027
  • Ref No: 5396790
  • Location: Germany

Conclusion Of A Non Exclusive Discount Agreement According To Section 130A Paragraph 8 Sgb V For Medicinal Products Containing The Active Ingredient L

  • Deadline: 27 Apr 2026

Concussion And Vestibular Physiotherapy Services

  • Deadline: 18 Mar 2026
  • Ref No: 4641976
  • Location: Germany

Medicines With The Active Ingredient Combination Oxycodone And Naloxone Atc N02Aa55

  • Deadline: 28 Feb 2026
  • Ref No: 4638957
  • Location: Germany

Medicines With The Active Ingredient Tacrolimus Atc L04Ad02

  • Deadline: 28 Feb 2026
  • Ref No: 5226107
  • Location: Germany

Medicines With The Active Ingredient Combination Vilanterol Umeclidinium Bromide And Fluticasone Furoate Atc R03Al08

  • Deadline: 31 Mar 2026
  • Ref No: 5976401
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Baclofen In The Dosage Form Inf

  • Deadline: 10 May 2026
  • Ref No: 5965319
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine As An Otc Medi

  • Deadline: 10 May 2026
  • Ref No: 5968352
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Acetylcysteine In The Dosage

  • Deadline: 10 May 2026
  • Ref No: 8271966
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Ciprofloxacin Oht Atr

  • Deadline: 10 May 2026
  • Ref No: 8280171
  • Location: Germany

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Prednisolone Atr

  • Deadline: 10 May 2026
WhatsApp Chat